Equillium Inc at H C Wainwright Global Life Sciences Conference Transcript
This presentation has not yet begun.
(Operator Instructions)
Good afternoon, everyone. My name is Ed White and I'm a biotech analyst at H.C. Wainwright. Good afternoon to all of you here in London. Good morning to all of you on the webcast. It's my pleasure to welcome Equillium today; presenting for the Company will be the Chairman and CEO, Daniel Bradbury.
Dan?
Thanks, Ed. Great pleasure to introduce Equillium to you here in London and also on the webcast.
Obviously the obligatory safe harbor statement and we'll comply with all of that.
Equillium, a Company we're developing a first in class antibody, itolizumab, EQ001. We're targeting novel checkpoint pathway CD6 and we're developing this antibody for the treatment of severe immuno-inflammatory disorders. As a result of recent understandings and new science around CD6, we believe this asset has the potential to be developed for a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |